EUVIMEDEUVIMED entdecken
Open Access

Early Pregnancy Plasma Per- and Polyfluoroalkyl Substances (PFAS) and Maternal Midlife Adiposity

Jordan A Burdeau iD, Briana J K Stephenson iD, Jorge E Chavarro, Shruthi Mahalingaiah, Emma V Preston, Marie-France Hivert, Emily Oken, Antonia M Calafat iD, Sheryl L Rifas-Shiman, Ami R Zota, Tamarra James-Todd iD

The Journal of Clinical Endocrinology & Metabolism · 2025

DOI: 10.1210/clinem/dgae542 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Jordan A Burdeau und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02215, USA. Hauptthemen laut MEDLINE: Fluorocarbons, Adiposity, Alkanesulfonic Acids, Prenatal Exposure Delayed Effects. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIEHS NIH HHS, National Institutes of Health's National Research Service Award, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Evidence suggests that exposure to per- and polyfluoroalkyl substances (PFAS) increases the risk of developing cardiometabolic disease risk factors. Limited research has evaluated associations between PFAS, assessed during pregnancy, a sensitive window for maternal endocrine effects, and long-term maternal adiposity.

Objective

Estimate associations of early pregnancy measures of individual PFAS, and PFAS mixtures, with maternal adiposity in midlife.

Methods

We studied 547 Project Viva participants with measures of early pregnancy (mean gestation 10.0 weeks; mean age 32.5 years) plasma concentrations of 6 PFAS and midlife adiposity outcomes (mean follow-up 17.7 years; mean age 50.7 years), including weight, waist circumference (WC), trunk fat mass (TFM), and total body fat mass (TBFM). We used linear regression and Bayesian Kernel Machine Regression (BKMR).

Results

Linear regression estimated higher midlife weight per doubling of perfluorooctane sulfonate (PFOS) (3.8 kg [95% CI: 1.6, 5.9]) and 2-(N-ethyl-perfluorooctane sulfonamido) acetate (2.3 kg [95% CI: 0.9, 3.7]). BKMR analyses of single PFAS plasma concentrations (comparing the 25th percentile concentration to the 75th percentile) showed a positive association between PFOS and midlife adiposity (weight: 7.7 kg [95% CI: 4.0, 11.5]; TFM: 1.2 kg [95% CI: 0.0, 2.3]; TBFM: 3.0 kg [95% CI: 0.8, 5.2]), but inverse associations with perfluorononanoate (weight: −6.0 kg [95% CI: −8.5, −3.5]; WC: −1.8 cm [95% CI: −3.2, −0.3]; TFM: −0.8 kg [95% CI: −1.5, −0.1]; TBFM: −1.4 kg [95% CI: −2.7, −0.3]) and perfluorohexane sulfonate (TFM: −0.8 kg [95% CI: −1.5, −0.1]; TBFM: −1.4 kg [95% CI: −2.6, −0.2]). No associations were observed with the overall PFAS mixture.

Conclusion

Select PFAS, assessed in pregnancy, may differentially affect maternal midlife adiposity, influencing later-life maternal cardiometabolic health.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FluorocarbonsAdiposityAlkanesulfonic AcidsPrenatal Exposure Delayed EffectsEnvironmental PollutantsHumansFemalePregnancyAdultMiddle AgedFollow-Up StudiesPregnancy Trimester, First

Stichwörter der Autor:innen

adipositymidlifeobesityper- and polyfluoroalkyl substances (PFAS)pregnancy

Substanzen

FluorocarbonsAlkanesulfonic Acidsperfluorooctane sulfonic acidEnvironmental Pollutantsperflexane

Autor:innen und Institutionen

  • Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02215, USA.
  • Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA 02215, USA.
  • Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA 02215, USA.
  • Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA 02215, USA.
  • Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Massachusetts General Hospital, Boston, MA 02114, USA.
  • Division of Chronic Disease Research Across the Lifecourse, Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA 02215, USA.

ORCID-Profile: Jordan A Burdeau, Briana J K Stephenson, Antonia M Calafat, Tamarra James-Todd

Förderung

  • NIEHS NIH HHS
  • National Institutes of Health's National Research Service Award
  • NIH HHS
  • NICHD NIH HHS
  • National Institutes of Health’s National Research Service Award
  • National Institutes of Health

Zitieren

APA

Burdeau, J. A., Stephenson, B. J. K., Chavarro, J. E., Mahalingaiah, S., Preston, E. V., Hivert, M. F., Oken, E., Calafat, A. M., Rifas-Shiman, S. L., Zota, A. R., & James-Todd, T. (2025). Early Pregnancy Plasma Per- and Polyfluoroalkyl Substances (PFAS) and Maternal Midlife Adiposity. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae542

Vancouver

Burdeau JA, Stephenson BJK, Chavarro JE, Mahalingaiah S, Preston EV, Hivert MF, et al. Early Pregnancy Plasma Per- and Polyfluoroalkyl Substances (PFAS) and Maternal Midlife Adiposity. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgae542

BibTeX
@article{Burdeau2025,
  author = {Burdeau, Jordan A and Stephenson, Briana J K and Chavarro, Jorge E and Mahalingaiah, Shruthi and Preston, Emma V and Hivert, Marie-France and Oken, Emily and Calafat, Antonia M and Rifas-Shiman, Sheryl L and Zota, Ami R and James-Todd, Tamarra},
  title = {Early Pregnancy Plasma Per- and Polyfluoroalkyl Substances (PFAS) and Maternal Midlife Adiposity},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  doi = {10.1210/clinem/dgae542}
}
Kostenlos starten →